Creative Biolabs

(Arg)9

Datasheet Mdsd
COA

Cat. No.: TDLD-0126-LD854

(Arg)9

(Arg)9 is an cell-penetrating peptide made up of 9 arginine residues capable of traversing plasma membranes. It has been shown that Arg9 destabilize and disrupt the phospholipid bilayer allowing flow of ions across the membrane. (Arg)9 peptide plays an important role in efficient cellular uptake. The guanidinium group is a critical structural determinant for tight and rapid interactions with cell membrane. The cationic guanidinium group can form electrostatic interactions with anionic cell membranes components such as phospholipids and sulphated proteoglycans. This interaction can trigger the activation of specific intracellular signalling and cell internalization via various pathways. (Arg)9 peptide is used to deliver a variety of functionally active cargos such as peptides,small interfering RNA,oligonucleotides,plasmid DNA and liposomes into mammalian cells and plant cells with high translocation efficiency. (Arg)9 peptide can also be used to form chemical linkages with the cargo and act as a carrier peptide. It's a Click (Arg)9.

Inquiry
SPECIFIC INQUIRY
Quantity:
Clear All Inquiry
For Research Use Only. Not for Diagnostic or Treatment Applications.
Category Cell-penetrating Peptides
CAS 143413-47-2
Formula C₅₄H₁₁₀N₃₆O₁₀
Molecular Weight 1423.72
Sequence (1-letter) H2N-RRRRRRRRR-OH
Sequence (3-letter) H2N-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-OH
Purity >95%
Form Solid/Powder
Shipping Ice pack
Storage Store at -20°C.
Shelf Life One Year

Click the button below to contact us or submit your feedback about this product.

Customer Reviews and Q&As
Related Products
Online Inquiry

Customer Review

Creatibe Biolabs' custom LNP was the only solution that successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high efficiency and low toxicity.”

Dr. Evelyn Reed

Postdoctoral Researcher, Leading University

Our siRNA candidate was failing due to off-target toxicity, but Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our preclinical program.”

Ben Carter

Project Manager

Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform was the key to unlocking our candidate's full therapeutic potential.”

Dr. Kenji Tanaka

Principal Scientist, Large Pharma Corp

Our oncology drug's efficacy was limited by poor tumor accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting we needed, dramatically increasing the drug's therapeutic index.”

Dr. Clara Schmidt

Senior Scientist, Oncology Innovations Inc.

We required a delivery system that would only release its payload in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed flawlessly, minimizing systemic exposure.”

David Chen

Formulation Scientist

Outstanding expertise in antibody engineering.The team's attention to detail and innovative approaches have sianificantly accelerated our development timeline.

Sarah L.

Senior Research Scientist

Contact us for more information Get free consultations